Sheldon Sloan, serving as the Chief Medical Officer at Spyre Therapeutics, Inc. (NASDAQ:SYRE), completed a full liquidation of his equity holdings on July 1, 2026. The executive sold 8,334 shares of common stock, realizing a total value of $730,895. This transaction was executed under the framework of a Rule 10b5-1 trading plan established on June 20, 2025, which governed both the acquisition and the subsequent sale of the shares.
The sales were structured in two distinct phases. Initially, 6,500 shares were disposed of at a weighted average price of $87.52, with individual transaction prices fluctuating between $87.03 and $87.99. Subsequently, an additional 1,834 shares were sold at a weighted average price of $88.34, with prices for these specific transactions ranging from $88.03 to $88.95. Prior to initiating these sales, Sloan acquired the identical number of shares by exercising stock options at a cost of $27.46 per share, totaling $228,851. Following the completion of these transactions, Sloan's direct holding in Spyre Therapeutics common stock stands at zero.
The timing of this divestment coincides with a period of substantial stock performance, with shares experiencing a 450% surge over the past year. Analysis from InvestingPro suggests the stock may currently be overvalued relative to its Fair Value, a factor that could have influenced the executive's decision to monetize the options. The stock options exercised represent the right to purchase 400,000 shares of Spyre Therapeutics common stock. The vesting schedule for these options included one quarter vesting on October 1, 2025, with the remainder vesting in monthly installments over the subsequent three years, contingent upon Sloan's continued employment with the company.
In parallel with the executive trading activity, Spyre Therapeutics has reported significant clinical developments. The company announced positive results from its phase 2 trial for the experimental drug SPY002, designed to treat ulcerative colitis. Known as the SKYLINE trial, the study demonstrated a statistically significant improvement in patient conditions, marked by a 10.7-point reduction in Robart's Histopathology Index score. These results prompted institutional investors to adjust their valuations. Stifel raised its price target for Spyre to $107, maintaining a Buy rating, citing strong data supporting SPY001 in ulcerative colitis. Similarly, Deutsche Bank increased its price target to $115, noting a competitor's setback as a contributing factor.
Further clinical progress was noted with the completion of enrollment for the SKYWAY basket trial, which evaluates SPY072 in various rheumatic diseases. Spyre plans to release topline data for rheumatoid arthritis in the third quarter of 2026 and for psoriatic arthritis and axial spondyloarthritis in the fourth quarter of 2026. Concurrently, other insider activity has been observed. Fairmount Healthcare Fund II L.P., a fund linked to Spyre's directors, sold a substantial number of shares totaling approximately $399.7 million, leaving the fund with zero shares in the company.